

# HTA ISPOR Health Technology Assessment Roundtables

## ISPOR 36th Health Technology Assessment Roundtable - Asia-Pacific *Health Technology Assessment of Medical Devices and Diagnostics in Asia-Pacific*

Saturday, 23 September 2017  
8:30AM-5:00PM  
Residence Room (2nd floor), Grand Hyatt Taipei  
Taipei, Taiwan

Delegates (26)

### ISPOR HTA Council (1)

**Finn Børllum Kristensen, MD, PhD**, Chair, ISPOR Health Technology Assessment Council, Former EUnetHTA Executive Committee Chairman and EUnetHTA Secretariat Director and Professor, Faculty of Health Sciences, University of Southern Denmark, Copenhagen, Denmark

### Australia (1)

**Stephen Goodall, PhD**, Professor of Health Economics and Deputy Director of Centre for Health Economics Research and Evaluation (CHERE), University of Technology Sydney, Sydney, Australia

### China (1)

**Kun Zhao, MD, PhD**, Professor and Director, Division of Health Technology Assessment, China National Health Development Research Center, National Health and Family Planning Commission (NHFPC), Beijing, China

### India (1)

**Jitendar Sharma, PhD**, CEO, Andhra Pradesh MedTech Zone Limited, and Executive Director, Kalam Institute of Health Technology, Andhra Pradesh, India

### Indonesia (3)

**Agusdini Banun, B.Pharm, MHA**, Secretary of the Directorate General of Pharmaceutical and Medical Devices, Ministry of Health, Jakarta, Indonesia

**Roy Himawan, Pharm.D., MPH**, Head of Planning Section, Secretariat of Directorate General of Pharmaceutical and Medical Devices, Ministry of Health, Jakarta, Indonesia

**Roni Syahputra, Pharm.D., MPH**, Staff of Pharmacoeconomic Section, Directorate of Pharmaceutical Service, Ministry of Health, Jakarta, Indonesia

### Japan (2)

**Hiroyuki Sakamaki, MBA, Dr.Med.Sci.**, Professor, School of Management, Tokyo University of Science Tokyo, Japan

**Ruoyan Gai, MSc, PhD**, Chief, Division of Policy Evaluation, Department of Health Policy and Chief, Division of Health Technology Assessment, Department of Clinical Epidemiology, National Center for Child Health and Development, Tokyo, Japan

Kazakhstan (1)

**Temirkhan Kulkhan, MD, MPH, MSc**, Healthcare Quality Coordinator, Kazakhstan Health Sector Technology Transfer & Institutional Reform Project, International Bank for Reconstruction and Development and Ministry of Health RK, Astana, Kazakhstan

Malaysia (1)

**Izzuna Mudla Mohamed Ghazali**, MBBS, MPH, MPH (Epidemiology), Senior Principle Assistant Director, Malaysian Health Technology, Assessment Section (MaHTAS), Medical Development Division, Ministry of Health, Kuala Lumpur, Malaysia

Mongolia (1)

**Tsetsegmaa Sanjjav, PhD**, Professor, School of Pharmacy, Mongolian National University of Medical Sciences, WHO Local Consultant, Ulaanbaatar, Mongolia

New Zealand (1)

**Richard Milne, PhD**, Managing Director, Health Outcomes Associates Ltd, and Associate Professor, School of Population Health, University of Auckland, Auckland, New Zealand

Philippines (3)

**Merla Rose D. Reyes**, Senior Social Insurance Specialist, Special Benefits Team, Philippine Health Insurance Corporation, Pasig City, Philippines

**Gemma Vecina**, Social Insurance Analyst I, Benefits Development & Research Department, Philippine Health Insurance Corporation, Pasig City, Philippines

Singapore (1)

**Kern Rei Chng, PhD**, Specialist (Device & Diagnostics), Evaluation and Appraisal, Agency for Care Effectiveness, Ministry of Health, Singapore

South Korea (1)

**Sukyeong Kim, PhD**, Director, Coordinating Center for National Health Clinical Research in National Evidence-Based Healthcare Collaborating Agency (NECA), Seoul, South Korea

Taiwan (6)

**Churn-Shiouh Gau, PhD**, Chief Executive Director, Center for Drug Evaluation (CDE), Taipei, Taiwan  
**Mao-Ting Sheen, MSC, MA**, Chief Secretary, National Health Insurance Administration (NHIA), Ministry of Health and Welfare, Taipei, Taiwan

**Jaw-Jou Kang, PhD**, Professor, Faculty of Pharmacy and Dean, School of Pharmaceutical Sciences, National Yang-Ming University, and Formal Director General, Taiwan Food & Drug Administration, Taipei, Taiwan

**Chee-Jen Chang, PhD**, Director, Clinical Informatics and Medical Statistics Research Center and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, TaoYuan, Taiwan

**Yen-Huei (Tony) Tarn, MS, PhD**, Associate Professor, School of Pharmacy, Kaohsiung Medical University Kaohsiung, Taiwan

**Raoh-Fang (Jasmine) Pwu, PhD, MS**, Director, National Hepatitis C Program Office, Ministry of Health and Welfare, Taipei, Taiwan

Thailand (2)

**Netnapis Suchonwanich**, Senior Advisor of Health Intervention and Technology Assessment Program (HITAP), Former Deputy Secretary General of National Health Security Office (NHSO) Bangkok, Thailand

**Suradech Dounghipsirikul, MA**, Researcher of Health Intervention and Technology Assessment Program (HITAP), Bangkok, Thailand

Vietnam (1)

**Tuan Quang Kieu, MSc**, Researcher of Health Insurance Department, Ministry of Health, Hanoi, Vietnam

[ISPOR Staff Members \(3\)](#)

**Nancy S. Berg**, CEO/Executive Director, ISPOR, Lawrenceville, NJ, USA

**Robert Selby**, Director, Global Networks - Asia-Pacific, ISPOR, Lawrenceville, NJ, USA

**Nancy Chen**, Associate Director and Content Strategist, Global Networks - Asia-Pacific, ISPOR, Lawrenceville, NJ, USA